Wei Li

机构：Texas Tech University, University of Science and Technology of China, Baylor College of Medicine, Chinese Academy of Sciences, Suzhou University of Science and Technology, Linyi People's Hospital, Xiangyang Central Hospital, Technical Institute of Physics and Chemistry, First People's Hospital of Chongqing, University of Chinese Academy of Sciences · ORCID：0000-0001-9566-8764

发表论文 132 篇 · 总被引 2408 次 · h-index 27

代表论文

• Inactivation of adenosine receptor 2A suppresses endothelial-to-mesenchymal transition and inhibits subretinal fibrosis in mice (2024 · Science Translational Medicine · 被引 20)
• Sodium tanshinone IIA sulfonate suppresses microglia polarization and neuroinflammation possibly via regulating miR-125b-5p/STAT3 axis to ameliorate neuropathic pain (2024 · European Journal of Pharmacology · 被引 19)
• Secretogranin III Selectively Promotes Vascular Leakage in the Deep Vascular Plexus of Diabetic Retinopathy (2023 · International Journal of Molecular Sciences · 被引 10)
• Profiling disease-selective drug targets: From proteomics to ligandomics (2022 · Drug Discovery Today · 被引 10)
• Progress in Traditional Chinese Medicine on Treatment of Diabetic Retinopathy (2022 · Natural Product Communications · 被引 7)
• CK2-dependent degradation of CBX3 dictates replication fork stalling and PARP inhibitor sensitivity (2024 · Science Advances · 被引 6)